November 20th 2024
Under the collaboration, the companies will create and test circVec DNA–LNP formulations with an eye toward potential therapeutic applications.
September 10th 2024
Alternative delivery methods for biologics continues to be explored that offer less invasive, less painful administration.
August 8th 2024
AAV and lentivirus both have pros and cons in their use for specific gene therapy applications.
July 8th 2024
Roche voluntarily recalled Susvimo’s ocular implant, insertion tool, and initial fill kit when test results did not satisfy company standards.
June 11th 2024
Swiss CDMO CordenPharma and Spain-based Certest will collaborate on the development of ionizable lipids for LNP formulations.